Cart
sales@molnova.com
Ro-3201195
CAS No. 249937-52-8
Ro-3201195( —— )
Catalog No. M36218 CAS No. 249937-52-8
Ro-3201195 is a novel orally available p38 MAPK inhibitor with high selectivity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 329 | In Stock |
|
| 5MG | 304 | In Stock |
|
| 10MG | 456 | In Stock |
|
| 25MG | 747 | In Stock |
|
| 50MG | 1004 | In Stock |
|
| 100MG | 1376 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 2753 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRo-3201195
-
NoteResearch use only, not for human use.
-
Brief DescriptionRo-3201195 is a novel orally available p38 MAPK inhibitor with high selectivity.
-
DescriptionRo-3201195 is a novel orally available p38 MAPK inhibitor with high selectivity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38 MAPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number249937-52-8
-
Formula Weight371.36
-
Molecular FormulaC19H18FN3O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESNC=1N(N=CC1C(=O)C2=CC(OCC(CO)O)=CC=C2)C3=CC=C(F)C=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
SKLB-163
SKLB-163 acts by downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK.
-
VX-745
A potent and selective p38α kinase inhibitor with IC50 of 9 nM; shows 20-fold selectivity for p38α over p38β (Ki=220 nM) and no significant inhibition for MAP kinases (with the exception of MKK6).
-
TAK-715
A potent, selective, orally active p38α MAPK inhibitor with IC50 of 7.1 nM.
